Selective Inhibitor of FLT3 Allows High-Risk AML Patients to Bridge to Stem Cell Transplant
December 10th 2012A unique targeted therapy, quizartinib, was able to clear leukemia cells from the bone marrow in more than 33% of patients with an aggressive form of acute myeloid leukemia marked by a mutation in the FLT3 gene.